Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue , 2015, Pages

  Ahmed, Nabil ^a   Brawley, Vita ^b   Hegde, Meenakshi ^b   Bielamowicz, Kevin ^b   Wakefield, Amanda ^a   Ghazi, Alexia ^a   Ashoori, Aidin ^a   Diouf, Oumar ^a   Gerken, Claudia ^a   Landi, Daniel ^a   Kalra, Mamta ^a   Yi, Zhongzhen ^c   Rooney, Cliona ^a   Dotti, Gianpietro ^a   Gee, Adrian ^a   Heslop, Helen ^b   Gottschalk, Stephen ^a   Powell, Suzanne ^d   Grossman, Robert ^d   Wels, Winfried ^e   Kew, Yzonne ^d   Baskin, David ^d   Zhang, Jonathan ^d   New, Pamela ^d   Hicks, John ^d   more..

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e CGT Frankfurt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON;

ARTICLE; CELL TRANSFER; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; GLIOBLASTOMA; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VOLUME;

EID: 85007303604     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-3-S2-O11     Document Type: Article

References (0)